Ezivac%25252525252525252520enema

# Ezivac Enema ## Overview Ezivac enema is a proprietary brand formulation containing **sodium phosphate** (monobasic sodium phosphate and dibasic sodium phosphate). It functions as a saline osmotic laxative, drawing water into the colon to induce distension and trigger peristalsis. ## Primary Indications * Relief of occasional constipation. * Bowel evacuation prior to rectal examinations or surgical procedures as directed by clinical protocol. ## Adult Dosing * **Standard Dose:** Administer one ready-to-use unit (delivering 118 mL) rectally as a single dose. * **Maximum:** Do not exceed one unit in a 24-hour period. ## Pediatric Dosing * **Children 12 years and older:** Same as adult dosing (one unit once daily). * **Children 2 to under 12 years:** Use of full-size adult units is generally not recommended. Pediatric formulations exist, but dosing must be strictly supervised by a clinician. * **Children under 2 years:** Contraindicated. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Patients with pre-existing renal insufficiency are at high risk for hyperphosphatemia and electrolyte disturbances. * **Cardiac/Electrolyte Abnormalities:** Exercise caution in patients with heart failure or those prone to hypocalcemia, hypernatremia, or hyperphosphatemia. ## Contraindications * Hypersensitivity to sodium phosphates or any enema components. * Suspected bowel obstruction, megacolon, or perforated bowel. * Active inflammatory bowel disease (e.g., ulcerative colitis). * Symptoms of appendicitis or undiagnosed abdominal pain. * Known renal failure. ## Adverse Effects * **Common:** Abdominal cramping, rectal irritation, or burning sensation. * **Serious:** Severe electrolyte imbalances (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), dehydration, metabolic acidosis, and rectal mucosal injury (from traumatic administration). ## Key Drug Interactions * **Diuretics/ACE Inhibitors/ARBs:** Concurrent use may increase the risk of renal injury and electrolyte disturbances. * **Calcium Channel Blockers:** Potential for enhanced adverse effects related to electrolyte shifts. * **Systemic Laxatives:** Concurrent use of other oral or rectal laxatives increases the risk of dehydration and electrolyte depletion. ## Monitoring * Monitor for signs of dehydration (e.g., thirst, confusion, oliguria). * Assess serum electrolytes (phosphate, calcium, sodium, potassium) in vulnerable populations (elderly or those with chronic kidney disease) if multiple doses are inadvertently administered. * Observe for signs of rectal bleeding or failure to evacuate. ## Clinical Pearls * **Administration:** Lubricate the tip before insertion to prevent rectal mucosal trauma. The patient should be placed in a left lateral decubitus position (Sims' position). * **Retention:** Advise the patient to retain the solution until a strong urge to defecate is felt (usually 2–5 minutes). * **Hydration:** Always encourage adequate fluid intake following administration to replace lost volume. * **Note:** If no evacuation occurs within 20–30 minutes, advise the patient to contact a healthcare provider; repeated self-administration is dangerous. *** *Disclaimer: This information is for educational purposes only. Drug information, protocols, and indications change frequently. Always verify the current prescribing information via official pharmacy references (such as Lexicomp or Micromedex) and your local institutional guidelines before prescribing or administering medication.*